Picture of Intelligent Ultrasound logo

IUG — Intelligent Ultrasound News Story

0.000.00%
gb flag iconLast trade - 00:00
IndustrialsHighly SpeculativeMicro CapMomentum Trap

Intelligent Ultrasnd - Notice of Results

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220425:nRSY1282Ja&default-theme=true

RNS Number : 1282J  Intelligent Ultrasound Group PLC  25 April 2022

Intelligent Ultrasound Group plc

(the "Company")

 

Notice of results

Analyst briefing

 

Intelligent Ultrasound Group plc (AIM: IUG), the ultrasound artificial
intelligence (AI) software and simulation company, announces it will issue its
unaudited preliminary results for the year ended 31 December 2021 on Tuesday,
3 May 2022.

 

The Company will host a briefing for analysts via ZOOM at 9.30am on Tuesday, 3
May. If you would like to register to dial in to the analyst briefing or
require further information, please contact Walbrook PR on 020 7933 8780 or
email intelligentultrasound@walbrookpr.com.

 

For further information, please contact:

 

 Intelligent Ultrasound Group plc                 www. intelligentultrasound.com (http://intelligentultrasound.com/)
 Stuart Gall, CEO                                 Tel: +44 (0)29 2075 6534

 Helen Jones, CFO

 Cenkos Securities - Nominated Advisor and Broker                                     Tel:  +44 (0)20 7397 8900
 Giles Balleny (Corporate Finance)
 Michael Johnson / Julian Morse (Sales)

 Walbrook PR             Tel: +44 (0)20 7933 8780 or intelligentultrasound@walbrookpr.com
 Anna Dunphy / Paul McManus                       Mob: +44 (0)7876 741 001 / Mob: +44 (0)7980 541 893

 

About Intelligent Ultrasound Group

 

Intelligent Ultrasound (AIM: IUG) is one of the world's leading 'classroom to
clinic' ultrasound companies, specialising in real-time hi-fidelity virtual
reality simulation for the ultrasound training market ('classroom') and
artificial intelligence-based clinical image analysis software tools for the
diagnostic medical ultrasound market ('clinic'). Based in Cardiff in
the UK and Atlanta in the US, the Group has two revenue streams:

 

Simulation

 

Focusses on real-time hi-fidelity ultrasound education and training through
simulation.  Its main products are the ScanTrainer obstetrics and
gynaecology training simulator, the HeartWorks echocardiography training
simulator, the BodyWorks Eve Point of Care and Emergency Medicine training
simulator with Covid module and the new BabyWorks Neonate and Paediatric
training simulator. To date over 1,350 simulators have been sold
to over 650 medical institutions around the world.

 

Clinical AI software

 

Focusses on developing deep learning-based algorithms to make ultrasound
machines smarter and more accessible using our proprietary ScanNav ultrasound
image analysis technology. Current products on the market utilising this
technology are GE Healthcare's SonoLyst software that is incorporated in
their Voluson SWIFT ultrasound machine; ScanNav Anatomy PNB that simplifies
ultrasound-guided needling by providing the user with real-time AI-based
anatomy highlighting for a range of medical procedures; and NeedleTrainer
that teaches real-time ultrasound guided needling and incorporates ScanNav
Anatomy PNB.

 

www.intelligentultrasound.com (http://www.intelligentultrasound.com/)

 

NOTE: ScanNav Anatomy PNB is not yet available for sale in the US or any other
territory requiring government approval for this type of product.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORGZGZDDDKGZZM

Recent news on Intelligent Ultrasound

See all news